MARIA LUCIA HIRATA KATAYAMA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
- Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil(2016) MAISTRO, Simone; TEIXEIRA, Natalia; ENCINAS, Giselly; KATAYAMA, Maria Lucia Hirata; NIEWIADONSKI, Vivian Dionisio Tavares; CABRAL, Larissa Garcia; RIBEIRO, Roberto Marques; GABURO JUNIOR, Nelson; GOUVEA, Ana Carolina Ribeiro Chaves de; CARRARO, Dirce Maria; SABINO, Ester Cerdeira; DIZ, Maria del Pilar Estevez; CHAMMAS, Roger; BOCK, Geertruida Hendrika de; FOLGUEIRA, Maria Aparecida Azevedo KoikeBackground: Approximately 8-15% epithelial ovarian cancer patients are BRCA1 or BRCA2 germline mutation carriers. Brazilian inhabitants may have peculiar genetic characteristics associated with ethnic diversity, and studies focusing on the entire BRCA1/BRCA2 gene sequencing in Brazilian ovarian cancer patients are still lacking. The aim of this study was to evaluate BRCA1/2 mutations, through entire gene sequencing, in a Brazilian population of women with epithelial ovarian cancer. Methods: In a cross sectional study performed in one reference centre for cancer treatment in Sao Paulo, Brazil, 100 patients diagnosed with epithelial ovarian cancer unselected for family history of breast and/or ovarian cancer were included. The complete coding sequence of BRCA1/2 genes was evaluated through Next-Generation or capillary sequencing. Large deletions were investigated through Multiplex Ligation-dependent Probe Amplification (MLPA). Results: Nineteen pathogenic mutations (BRCA1: n = 17 and BRCA2: n = 2) featuring 14 different mutations, including two large deletions in BRCA1 (exon 1-2 deleted and exon 5-7 deleted) were identified. Three mutations were detected more than once (c.3331_3334delCAAG, c.5266dupC and c.4484G > T). Two novel frameshift mutations were identified, one in BRCA1 (c.961_962delTG) and one in BRCA2 (c.1963_1963delC). BRCA1/2 mutations were seen in 35.5% of the patients with first and/or second-degree relatives with breast and/or ovarian cancer. Nineteen variants of uncertain significance (VUS) were detected (BRCA1: n = 2 and BRCA2: n = 17), including five distinct missense variants (BRCA1: c. 5348 T > C; BRCA2: c.2350A > G, c.3515C > T, c.7534C > T, and c.8351G > A). Conclusions: Among epithelial ovarian cancer patients unselected for family history of cancer, 19% were BRCA1/2 germline mutation carriers. Almost 3/4 of the BRCA mutations, including two large deletions, were detected only once. Our work emphasizes the need of entire gene sequencing and MLPA screening in Brazil.
- Transcriptional effects of 1,25 dihydroxyvitamin D-3 physiological and supra-physiological concentrations in breast cancer organotypic culture(2013) MILANI, Cintia; KATAYAMA, Maria Lucia Hirata; LYRA, Eduardo Carneiro de; WELSH, JoEllen; CAMPOS, Laura Tojeiro; BRENTANI, M. Mitzi; MACIEL, Maria do Socorro; ROELA, Rosimeire Aparecida; VALLE, Paulo Roberto del; GOES, Joao Carlos Guedes Sampaio; NONOGAKI, Suely; TAMURA, Rodrigo Esaki; FOLGUEIRA, Maria Aparecida Azevedo KoikeBackground: Vitamin D transcriptional effects were linked to tumor growth control, however, the hormone targets were determined in cell cultures exposed to supra physiological concentrations of 1,25(OH)(2)D-3 (50-100nM). Our aim was to evaluate the transcriptional effects of 1,25(OH)(2)D-3 in a more physiological model of breast cancer, consisting of fresh tumor slices exposed to 1,25(OH)(2)D-3 at concentrations that can be attained in vivo. Methods: Tumor samples from post-menopausal breast cancer patients were sliced and cultured for 24 hours with or without 1,25(OH)(2)D-3 0.5nM or 100nM. Gene expression was analyzed by microarray (SAM paired analysis, FDR <= 0.1) or RT-qPCR (p <= 0.05, Friedman/Wilcoxon test). Expression of candidate genes was then evaluated in mammary epithelial/breast cancer lineages and cancer associated fibroblasts (CAFs), exposed or not to 1,25(OH)(2)D-3 0.5nM, using RT-qPCR, western blot or immunocytochemistry. Results: 1,25(OH)(2)D-3 0.5nM or 100nM effects were evaluated in five tumor samples by microarray and seven and 136 genes, respectively, were up-regulated. There was an enrichment of genes containing transcription factor binding sites for the vitamin D receptor (VDR) in samples exposed to 1,25(OH)(2)D-3 near physiological concentration. Genes up-modulated by both 1,25(OH)(2)D-3 concentrations were CYP24A1, DPP4, CA2, EFTUD1, TKTL1, KCNK3. Expression of candidate genes was subsequently evaluated in another 16 samples by RT-qPCR and up-regulation of CYP24A1, DPP4 and CA2 by 1,25(OH)(2)D-3 was confirmed. To evaluate whether the transcripitonal targets of 1,25(OH)(2)D-3 0.5nM were restricted to the epithelial or stromal compartments, gene expression was examined in HB4A, C5.4, SKBR3, MDA-MB231, MCF-7 lineages and CAFs, using RT-qPCR. In epithelial cells, there was a clear induction of CYP24A1, CA2, CD14 and IL1RL1. In fibroblasts, in addition to CYP24A1 induction, there was a trend towards up-regulation of CA2, IL1RL1, and DPP4. A higher protein expression of CD14 in epithelial cells and CA2 and DPP4 in CAFs exposed to 1,25(OH)(2)D-3 0.5nM was detected. (Continued on next page) (Continued from previous page) Conclusions: In breast cancer specimens a short period of 1,25(OH)(2)D-3 exposure at near physiological concentration modestly activates the hormone transcriptional pathway. Induction of CYP24A1, CA2, DPP4, IL1RL1 expression appears to reflect 1,25(OH)(2)D-3 effects in epithelial as well as stromal cells, however, induction of CD14 expression is likely restricted to the epithelial compartment.